ライフサイエンスコーパス: we assigned

1 metadata and responses to a set of voltage-clamp protocols, we assigned 2378 models of voltage- and calcium-gated ion cha

2 In this multicenter, randomized, controlled trial, we assigned 240 severely injured patients (Injury Severity Sc

3 Between June 1, 2015, and July 5, 2017, we assigned 270 patients to treatment: 134 to aspiration firs

4 In this 42-week, double-blind, crossover trial, we assigned 295 patients who were at least 12 years of age an

5 In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to rece

6 lticenter, randomized, controlled trial in the Netherlands, we assigned 40,373 women between the ages of 50 and 75 years

7 In a randomized, noninferiority, multicenter trial, we assigned 400 adults in stable condition who had endocardit

8 Between Jan 7, 2016, and May 25, 2017, we assigned 419 patients to treatment: 210 to nivolumab and 2

9 In this open-label, multicohort study, we assigned 47 patients with untreated or relapsed BPDCN to r

10 In this randomized, double-blind, event-driven trial, we assigned 4822 patients who had heart failure with preserve

11 Based on annual residential postal codes, we assigned 5-y running average concentrations of fine partic

12 ctive, randomized exploratory safety and feasibility trial, we assigned 50 patients with anterior STEMI to LV unloading b

13 hase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New Yor

14 Between Jan 29, 2016, and May 2, 2018, we assigned 80 patients to receive either liraglutide (n=53)

15 randomized, double-blind trial of high-dose erythropoietin, we assigned 941 infants who were born at 24 weeks 0 days to 2

16 hed between 2008 and 2016 and could be matched with PubMed, we assigned a gender to first and last authors on the basis o

17 For contributory and no role cases, we assigned a primary cause of death.

18 We assigned a recurrence score (RS) to each cohort, defining

19 We assigned a relative rank of importance to every base in a

20 We assigned a specific number of points to each BE risk facto

21 In a randomized, controlled trial, we assigned a subgroup of patients who were undergoing TAVI a

22 We assigned adults with migraine, with or without aura, in a

23 We assigned annual exposures by each child's home and school

24 We assigned children with negative answers to all three quest

25 We assigned CWSs and counties MCL compliance categories (High

26 We assigned estimates of exposure to greenness derived from r

27 By integrating over the whole phytoplankton community, we assigned functional changes based on altered metabolite co

28 In the first cohort, we assigned (in a 3:1 ratio) patients who had the option of u

29 In a multicenter, randomized, controlled trial, we assigned, in a 1:1 ratio, mechanically ventilated ICU pati

30 In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependen

31 multicenter, randomized, open-label, parallel-group trial, we assigned, in a 3:1 ratio, children 6 to 13 years of age wh

32 We assigned metrics of UNGD activity by phase (pad preparatio

33 We assigned mice to a conventional diet, an AhR ligand-free d

34 In this single-center, randomized, nonblinded trial, we assigned participants with chronic edema of the leg and re

35 In this prospective, randomized trial, we assigned patients between the ages of 40 and 85 years who

36 ouble-blind, randomized, placebo-controlled, phase 2 trial, we assigned patients to receive low-dose crizanlizumab (2.5 m

37 In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus

38 uble-masked, placebo-controlled, phase 3 multicenter trial, we assigned patients with active thyroid eye disease in a 1:1

39 In this multicenter, randomized trial, we assigned patients with ARDS to receive either conservative

40 In a randomized, controlled, double-blind trial, we assigned patients with chronic coronary disease to receive

41 In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one

42 In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chr

43 We assigned people to cognitively defined subgroups on the ba

44 We assigned phenotype status using a validated algorithm.

45 We assigned pre-HD subjects to subgroups of fast, intermediat

46 Using annual mailing address, we assigned time-varying contextual variables and 3-y moving-

47 rmation, all variants showed a signal at 1400 cm(-1), which we assigned to the nu7'a marker band of the CO stretching mod

48 n this factorial, open-label, randomized, controlled trial, we assigned Ugandan and Malawian children 2 months to 12 year

49 We assigned women living with HIV and their child (oldest 3-8

50 We assigned women living with HIV and their child (oldest 3-8